Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach

Proteome Science

Volumn 9, Issue , 2011, Pages

  Collet, Brigitte ^a   Guitton, Nathalie ^b   Saïkali, Stephan ^c   Avril, Tony ^a   Pineau, Charles ^b   Hamlat, Abderrahmane ^c   Mosser, Jean ^d   Quillien, Véronique ^a,d  

^a Centre Régional de Lutte Contre Le Cancer   (France)

^b Campus de Beaulieu ^*  (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA TUBULIN; APOLIPOPROTEIN A1; BETA TUBULIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; COLLAPSIN RESPONSE MEDIATOR PROTEIN 4; DIHYDROPYRIMIDINASE RELATED PROTEIN 3; ENDOPLASMIC RETICULUM RESIDENT PROTEIN 60; GAMMA GLUTAMYL HYDROLASE; GLIAL FIBRILLARY ACID PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN 27; HEMOGLOBIN; HUMAN SERUM ALBUMIN; MANGANESE SUPEROXIDE DISMUTASE; MORTALIN; PREALBUMIN; PROTEIN; PROTEIN DISULFIDE ISOMERASE A3; PROTEOME; UBIQUITINE CARBOXYL TERMINAL HYDROLASE L1; UNCLASSIFIED DRUG; VIMENTIN;

ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DIFFERENCE GEL ELECTROPHORESIS; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 79953647766     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-9-16     Document Type: Article

References (51)

1. Stark AM, Nabavi A, Mehdorn HM, Blomer U. Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 2005, 63:162-169. 10.1016/j.surneu.2004.01.028, 15680662.
2. Sathornsumetee S, Rich JN. Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci 2008, 1142:108-132. 10.1196/annals.1444.009, 18990124.
3. Chi AS, Norden AD, Wen PY. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics 2009, 6:513-526. 10.1016/j.nurt.2009.04.010, 19560741.
4. Yamanaka R. Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg Rev 2009, 32:265-273. 10.1007/s10143-009-0189-1, 19214609.
5. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812. 10.1126/science.1164382, 2820389, 18772396.
6. Whittle IR, Short DM, Deighton RF, Kerr LE, Smith C, McCulloch J. Proteomic analysis of gliomas. Br J Neurosurg 2007, 21:576-582. 10.1080/02688690701721691, 18071984.
7. Melchior K, Tholey A, Heisel S, Keller A, Lenhof HP, Meese E, et al. Proteomic study of human glioblastoma multiforme tissue employing complementary two-dimensional liquid chromatography- and mass spectrometry-based approaches. J Proteome Res 2009, 8:4604-4614. 10.1021/pr900420b, 19673542.
8. Khalil AA. Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci 2007, 98:201-213. 10.1111/j.1349-7006.2007.00374.x, 17233837.
9. Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Drenou B, et al. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol 2007, 81:139-148. 10.1007/s11060-006-9220-3, 17004103.
10. Niclou SP, Fack F, Rajcevic U. Glioma proteomics: Status and perspectives. J Proteomics 2010, 73:1823-1838. 10.1016/j.jprot.2010.03.007, 20332038.
11. Gharbi S, Gaffney P, Yang A, Zvelebil MJ, Cramer R, Waterfield MD, et al. Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol Cell Proteomics 2002, 1:91-98. 10.1074/mcp.T100007-MCP200, 12096126.
12. Zhou G, Li H, DeCamp D, Chen S, Shu H, Gong Y, et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 2002, 1:117-124. 10.1074/mcp.M100015-MCP200, 12096129.
13. Deighton RF, McGregor R, Kemp J, McCulloch J, Whittle IR. Glioma pathophysiology: insights emerging from proteomics. Brain Pathol 2010, 20:691-703. 10.1111/j.1750-3639.2010.00376.x, 20175778.
14. Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, Kamitani H, et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 2003, 309:558-566. 10.1016/j.bbrc.2003.08.029, 12963026.
15. Fleming CE, Nunes AF, Sousa MM. Transthyretin: more than meets the eye. Prog Neurobiol 2009, 89:266-276. 10.1016/j.pneurobio.2009.07.007, 19665514.
16. Park CK, Jung JH, Park SH, Jung HW, Cho BK. Multifarious proteomic signatures and regional heterogeneity in glioblastomas. J Neurooncol 2009, 94:31-39. 10.1007/s11060-009-9805-8, 19219580.
17. Leandro-Garcia LJ, Leskela S, Landa I, Montero-Conde C, Lopez-Jimenez E, Leton R, et al. Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton (Hoboken) 2010, 67:214-223.
18. Jung CS, Foerch C, Schanzer A, Heck A, Plate KH, Seifert V, et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 2007, 130:3336-3341. 10.1093/brain/awm263, 17998256.
19. Chumbalkar VC, Subhashini C, Dhople VM, Sundaram CS, Jagannadham MV, Kumar KN, et al. Differential protein expression in human gliomas and molecular insights. Proteomics 2005, 5:1167-1177. 10.1002/pmic.200401202, 15759318.
20. Ordys BB, Launay S, Deighton RF, McCulloch J, Whittle IR. The role of mitochondria in glioma pathophysiology. Mol Neurobiol 2010, 42:64-75. 10.1007/s12035-010-8133-5, 20414816.
21. Park CK, Jung JH, Moon MJ, Kim YY, Kim JH, Park SH, et al. Tissue expression of manganese superoxide dismutase is a candidate prognostic marker for glioblastoma. Oncology 2009, 77:178-181. 10.1159/000231888, 19641337.
22. Ria F, Landriscina M, Remiddi F, Rosselli R, Iacoangeli M, Scerrati M, et al. The level of manganese superoxide dismutase content is an independent prognostic factor for glioblastoma. Biological mechanisms and clinical implications. Br J Cancer 2001, 84:529-534. 10.1054/bjoc.2000.1594, 2363764, 11207049.
23. Corti S, Locatelli F, Papadimitriou D, Donadoni C, Salani S, Del BR, et al. Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells 2006, 24:975-985. 10.1634/stemcells.2005-0217, 16293577.
24. Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 2010, 5:e10277. 10.1371/journal.pone.0010277, 2858084, 20422001.
25. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567. 10.1016/j.stem.2007.08.014, 2423808, 18371393.
26. Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010, 102:340-351. 10.1093/jnci/djp535, 2831049, 20164446.
27. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010, 16:45-55. 10.1158/1078-0432.CCR-09-1630, 2874875, 20028757.
28. Son MJ, Woolard K, Nam DH, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009, 4:440-452. 10.1016/j.stem.2009.03.003, 19427293.
29. Tchoghandjian A, Baeza N, Colin C, Cayre M, Metellus P, Beclin C, et al. A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathol 2010, 20:211-221. 10.1111/j.1750-3639.2009.00269.x, 19243384.
30. Takano S, Wadhwa R, Yoshii Y, Nose T, Kaul SC, Mitsui Y. Elevated levels of mortalin expression in human brain tumors. Exp Cell Res 1997, 237:38-45. 10.1006/excr.1997.3754, 9417864.
31. Wadhwa R, Takano S, Kaur K, Deocaris CC, Pereira-Smith OM, Reddel RR, et al. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer 2006, 118:2973-2980. 10.1002/ijc.21773, 16425258.
32. Iwadate Y, Sakaida T, Hiwasa T, Nagai Y, Ishikura H, Takiguchi M, et al. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 2004, 64:2496-2501. 10.1158/0008-5472.CAN-03-1254, 15059904.
33. Zhang R, Tremblay TL, McDermid A, Thibault P, Stanimirovic D. Identification of differentially expressed proteins in human glioblastoma cell lines and tumors. Glia 2003, 42:194-208. 10.1002/glia.10222, 12655603.
34. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006, 5:2592-2601. 10.4161/cc.5.22.3448, 17106261.
35. Odreman F, Vindigni M, Gonzales ML, Niccolini B, Candiano G, Zanotti B, et al. Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome Res 2005, 4:698-708. 10.1021/pr0498180, 15952716.
36. Coe H, Michalak M. ERp57, a multifunctional endoplasmic reticulum resident oxidoreductase. Int J Biochem Cell Biol 2010, 42:796-799. 10.1016/j.biocel.2010.01.009, 20079872.
37. Fountoulakis M, Hardmaier R, Schuller E, Lubec G. Differences in protein level between neonatal and adult brain. Electrophoresis 2000, 21:673-678. 10.1002/(SICI)1522-2683(20000201)21:3<673::AID-ELPS673>3.0.CO;2-Y, 10726776.
38. Lubec G, Nonaka M, Krapfenbauer K, Gratzer M, Cairns N, Fountoulakis M. Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. J Neural Transm Suppl 1999, 57:161-177.
39. Weitzdoerfer R, Fountoulakis M, Lubec G. Aberrant expression of dihydropyrimidinase related proteins-2,-3 and -4 in fetal Down syndrome brain. J Neural Transm Suppl 2001, 95-107.
40. Yoshida H, Watanabe A, Ihara Y. Collapsin response mediator protein-2 is associated with neurofibrillary tangles in Alzheimer's disease. J Biol Chem 1998, 273:9761-9768. 10.1074/jbc.273.16.9761, 9545313.
41. Byk T, Ozon S, Sobel A. The Ulip family phosphoproteins--common and specific properties. Eur J Biochem 1998, 254:14-24. 10.1046/j.1432-1327.1998.2540014.x, 9652388.
42. Choi YL, Kim CJ, Matsuo T, Gaetano C, Falconi R, Suh YL, et al. HUlip, a human homologue of unc-33-like phosphoprotein of Caenorhabditis elegans; Immunohistochemical localization in the developing human brain and patterns of expression in nervous system tumors. J Neurooncol 2005, 73:19-27. 10.1007/s11060-004-3013-3, 15933812.
43. Gu Y, Hamajima N, Ihara Y. Neurofibrillary tangle-associated collapsin response mediator protein-2 (CRMP-2) is highly phosphorylated on Thr-509, Ser-518, and Ser-522. Biochemistry (Mosc) 2000, 39:4267-4275.
44. Cole AR, Causeret F, Yadirgi G, Hastie CJ, McLauchlan H, McManus EJ, et al. Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo. J Biol Chem 2006, 281:16591-16598. 10.1074/jbc.M513344200, 1805471, 16611631.
45. Kobeissy FH, Ottens AK, Zhang Z, Liu MC, Denslow ND, Dave JR, et al. Novel differential neuroproteomics analysis of traumatic brain injury in rats. Mol Cell Proteomics 2006, 5:1887-1898. 10.1074/mcp.M600157-MCP200, 16801361.
46. Setsuie R, Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int 2007, 51:105-111. 10.1016/j.neuint.2007.05.007, 17586089.
47. Karp NA, Lilley KS. Maximising sensitivity for detecting changes in protein expression: experimental design using minimal CyDyes. Proteomics 2005, 5:3105-3115. 10.1002/pmic.200500083, 16035117.
48. Engelen K, Sifrim A, Van de PB, Laukens K, Arckens L, Marchal K. Alternative experimental design with an applied normalization scheme can improve statistical power in 2D-DIGE experiments. J Proteome Res 2010, 9:4919-4926. 10.1021/pr100010u, 20681517.
49. McDonald JH. Handbook of Biological Statistics 2009, 118-122. Sparky House Publishing, Baltimore, Maryland. Ref Type: Generic, 2.
50. Rolland AD, Evrard B, Guitton N, Lavigne R, Calvel P, Couvet M, et al. Two-dimensional fluorescence difference gel electrophoresis analysis of spermatogenesis in the rat. J Proteome Res 2007, 6:683-697. 10.1021/pr060436z, 17269725.
51. Romero-Calvo I, Ocon B, Martinez-Moya P, Suarez MD, Zarzuelo A, Martinez-Augustin O, et al. Reversible Ponceau staining as a loading control alternative to actin in Western blots. Anal Biochem 2010, 401:318-320. 10.1016/j.ab.2010.02.036, 20206115.